Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

The Prostate

Showing results (491-500 of 6,084) with videos related to

Pageof 609
Sort By:
The Prostate|July 1, 1996
Isoforms of prostate-specific antigen in serum: a result of the glycosylation process in dysplastic prostatic cells?K Jung, M Lein, W Henke, et al.
The Prostate|June 1, 1996
Effect of prostatic growth factor, basic fibroblast growth factor, epidermal growth factor, and steroids on the proliferation of human fetal prostatic fibroblastsD Luo, Y Lin, X Liu, et al.
The Prostate|June 1, 1996
Regulation of prostatic growth and function by peptide growth factorsZ Culig, A Hobisch, M V Cronauer, et al.
The Prostate|February 1, 1997
Race and the histologic grade of prostate cancerV L Freeman, J Leszczak, R S Cooper
The Prostate|May 1, 1996
Loss of heterozygosity on chromosomes 10 and 17 in clinically localized prostate carcinomaM M Ittmann
The Prostate|May 1, 1996
Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatmentM Maffezzini, A Simonato, C Fortis
The Prostate|May 1, 1996
Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasiaH Weisser, S Tunn, B Behnke, et al.
The Prostate|May 1, 1996
Effect of aromatase inhibitor, TZA-2209, on the prostate of androstenedione-treated castrated dogs: changes in prostate volume and histopathological findingsK Suzuki, K Ito, Y Tamura, et al.
The Prostate|February 17, 2006
IGF-I secretion by prostate carcinoma cells does not alter tumor-bone cell interactions in vitro or in vivoJanet Rubin, Xian Fan, Jill Rahnert, et al.
The Prostate|February 24, 2006
Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer modelHelena Dzojic, Angelica Loskog, Thomas H Tötterman, et al.
Pageof 609

Showing results (491-500 of 6,084) with videos related to

Sort By:
Pageof 609
The Prostate|July 1, 1996
Isoforms of prostate-specific antigen in serum: a result of the glycosylation process in dysplastic prostatic cells?K Jung, M Lein, W Henke, et al.
The Prostate|June 1, 1996
Effect of prostatic growth factor, basic fibroblast growth factor, epidermal growth factor, and steroids on the proliferation of human fetal prostatic fibroblastsD Luo, Y Lin, X Liu, et al.
The Prostate|June 1, 1996
Regulation of prostatic growth and function by peptide growth factorsZ Culig, A Hobisch, M V Cronauer, et al.
The Prostate|February 1, 1997
Race and the histologic grade of prostate cancerV L Freeman, J Leszczak, R S Cooper
The Prostate|May 1, 1996
Loss of heterozygosity on chromosomes 10 and 17 in clinically localized prostate carcinomaM M Ittmann
The Prostate|May 1, 1996
Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatmentM Maffezzini, A Simonato, C Fortis
The Prostate|May 1, 1996
Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasiaH Weisser, S Tunn, B Behnke, et al.
The Prostate|May 1, 1996
Effect of aromatase inhibitor, TZA-2209, on the prostate of androstenedione-treated castrated dogs: changes in prostate volume and histopathological findingsK Suzuki, K Ito, Y Tamura, et al.
The Prostate|February 17, 2006
IGF-I secretion by prostate carcinoma cells does not alter tumor-bone cell interactions in vitro or in vivoJanet Rubin, Xian Fan, Jill Rahnert, et al.
The Prostate|February 24, 2006
Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer modelHelena Dzojic, Angelica Loskog, Thomas H Tötterman, et al.
Pageof 609